MCID: HPT014
MIFTS: 49

Hepatorenal Syndrome

Categories: Gastrointestinal diseases, Liver diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Hepatorenal Syndrome

MalaCards integrated aliases for Hepatorenal Syndrome:

Name: Hepatorenal Syndrome 12 75 53 55 44 15 72 33
Hepato-Renal Syndrome 53

Classifications:



External Ids:

Disease Ontology 12 DOID:11823
ICD9CM 35 572.4
MeSH 44 D006530
NCIt 50 C113400
SNOMED-CT 68 51292008
ICD10 33 K76.7
UMLS 72 C0019212

Summaries for Hepatorenal Syndrome

NIH Rare Diseases : 53 Hepatorenal syndrome is a form of impaired kidney function that occurs in individuals with advanced chronic liver disease. As many as 40% of individuals with cirrhosis and ascites will develop hepatorenal syndrome. Symptoms may include fatigue, abdominal pain, and a general feeling of ill health (malaise). There are two distinct types of hepatorenal syndrome. Type I progresses quickly (within days), leading to kidney failure. Individuals with type I typically have dramatically reduced urine output, edema, and jaundice, and often suffer from hepatic encephalopathy. Type II progresses more slowly, over weeks or months, and the symptoms are less severe. The cause of hepatorenal syndrome is unknown. A contributing factor seems to be a narrowing of the blood vessels that connect into the kidneys. This causes a decrease in blood flow to the kidneys, impairing their function. In some cases, triggers or precipitating factors (infections, blood loss from the gastrointestinal tract, low blood pressure) are involved. Treatment is aimed at helping the liver work better and maintaining kidney function. In many cases, a liver transplant is needed. In some cases, individuals also need a kidney transplant.

MalaCards based summary : Hepatorenal Syndrome, also known as hepato-renal syndrome, is related to hepatic coma and portal hypertension. An important gene associated with Hepatorenal Syndrome is ALB (Albumin), and among its related pathways/superpathways are FOXA2 and FOXA3 transcription factor networks and IL1 and megakaryocytes in obesity. The drugs Clavulanate and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and bone, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 An acute kidney failure that is characterized by severe renal vasoconstriction.

Wikipedia : 75 Hepatorenal syndrome (often abbreviated HRS) is a life-threatening medical condition that consists of... more...

Related Diseases for Hepatorenal Syndrome

Diseases related to Hepatorenal Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 227)
# Related Disease Score Top Affiliating Genes
1 hepatic coma 31.4 F2 ALB
2 portal hypertension 31.3 F2 EDN1 ALB
3 acute liver failure 31.2 F2 ALB
4 esophageal varix 30.9 F2 ALB
5 hepatic encephalopathy 30.9 F2 ALB
6 anuria 30.7 REN ALB
7 hepatitis a 30.7 F2 ALB
8 bilirubin metabolic disorder 30.7 F2 ALB
9 compartment syndrome 30.6 F2 ALB
10 hepatopulmonary syndrome 30.6 EDN1 ALB
11 cholecystitis 30.4 F2 ALB
12 alcoholic hepatitis 30.4 F2 ALB
13 infantile liver failure syndrome 1 30.4 F2 ALB
14 biliary tract disease 30.4 F2 ALB
15 hepatitis e 30.3 F2 ALB
16 alcoholic liver cirrhosis 30.3 F2 ALB
17 obstructive jaundice 29.9 REN F2 EDN1 ALB
18 acute kidney tubular necrosis 29.9 NPPA IL18 CST3 ALB
19 congestive heart failure 29.8 REN NPPA EDN1
20 endocarditis 29.6 F2 ALB
21 acute kidney failure 29.6 REN NPPA IL18 CST3 ALB
22 pulmonary hypertension 29.5 REN NPPA EDN1
23 eclampsia 29.5 REN F2 EDN1 ALB
24 pulmonary edema 29.3 REN NPPA F2 EDN1
25 liver cirrhosis 29.1 REN NPPA F2 EDN1 AQP2 ALB
26 pre-eclampsia 29.0 REN NPPA F2 EDN1
27 kidney disease 28.6 REN NPPA EDN1 CST3 AQP2 ALB
28 peroxisome biogenesis disorder 1a 11.8
29 joubert syndrome with oculorenal anomalies 11.8
30 liver disease 10.7
31 peritonitis 10.6
32 benign essential hypertension 10.6 REN ALB
33 kidney papillary necrosis 10.6 REN ALB
34 orthostatic proteinuria 10.6 REN ALB
35 malignant renovascular hypertension 10.5 REN EDN1
36 malignant hypertensive renal disease 10.5 REN EDN1
37 non-a-e hepatitis 10.5 F2 ALB
38 antipyrine metabolism 10.5 F2 ALB
39 malignant secondary hypertension 10.5 REN EDN1
40 epstein-barr virus hepatitis 10.5 F2 ALB
41 perinephritis 10.5 REN EDN1
42 fournier gangrene 10.5 F2 ALB
43 abdominal tuberculosis 10.5 F2 ALB
44 hepatic tuberculosis 10.5 F2 ALB
45 kwashiorkor 10.5 F2 ALB
46 intestinal impaction 10.5 REN F2
47 splenic disease 10.5 F2 ALB
48 ascending cholangitis 10.5 F2 ALB
49 renal tuberculosis 10.5 REN EDN1
50 cardiac tamponade 10.5 REN F2

Comorbidity relations with Hepatorenal Syndrome via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alcoholic Liver Cirrhosis
Deficiency Anemia Heart Disease
Hepatic Encephalopathy Portal Hypertension

Graphical network of the top 20 diseases related to Hepatorenal Syndrome:



Diseases related to Hepatorenal Syndrome

Symptoms & Phenotypes for Hepatorenal Syndrome

MGI Mouse Phenotypes related to Hepatorenal Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.81 ALB AQP2 AVPR1A CST3 EDN1 F2
2 cardiovascular system MP:0005385 9.8 AVPR1A CST3 EDN1 F2 IL18 NPPA
3 muscle MP:0005369 9.5 ALB AVPR1A CST3 EDN1 IL18 NPPA
4 renal/urinary system MP:0005367 9.02 ALB AQP2 EDN1 NPPA REN

Drugs & Therapeutics for Hepatorenal Syndrome

Drugs for Hepatorenal Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
2
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
3
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
4
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
5
Azithromycin Approved Phase 4 83905-01-5 447043 55185
6
Vancomycin Approved Phase 4 1404-90-6 441141 14969
7
Norfloxacin Approved Phase 4 70458-96-7 4539
8
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
9
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
10
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
11
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
12
Atorvastatin Approved Phase 4 134523-00-5 60823
13
Tranexamic Acid Approved Phase 4 1197-18-8 5526
14
Isoleucine Approved, Investigational, Nutraceutical Phase 4 443-79-8, 73-32-5 6306
15
Adefovir Investigational Phase 4 106941-25-7
16 Amoxicillin-Potassium Clavulanate Combination Phase 4
17 Nucleic Acid Synthesis Inhibitors Phase 4
18 Reverse Transcriptase Inhibitors Phase 4
19 Antitubercular Agents Phase 4
20 Gastrointestinal Agents Phase 4
21 Pharmaceutical Solutions Phase 4
22 Cytochrome P-450 Enzyme Inhibitors Phase 4
23 Topoisomerase Inhibitors Phase 4
24 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
25 diuretics Phase 4
26 Natriuretic Agents Phase 4
27 Sodium Potassium Chloride Symporter Inhibitors Phase 4
28 Liver Extracts Phase 4
29 Coagulants Phase 4
30 Hemostatics Phase 4
31 Lipid Regulating Agents Phase 4
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
33 Hypolipidemic Agents Phase 4
34 Anticholesteremic Agents Phase 4
35 Antimetabolites Phase 4
36 Antifibrinolytic Agents Phase 4
37 valine Phase 4
38 leucine Phase 4
39 Anti-Bacterial Agents Phase 4
40 Anti-Infective Agents Phase 4
41 Antibiotics, Antitubercular Phase 4
42 Anticoagulants Phase 4
43 Dextrans Phase 4
44 Plasma Substitutes Phase 4
45 Blood Substitutes Phase 4
46
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
47
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
48
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
49
Simvastatin Approved Phase 3 79902-63-9 54454
50
Nitric Oxide Approved Phase 3 10102-43-9 145068

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Unknown status NCT02489864 Phase 4 Terlipressin
2 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Unknown status NCT01530711 Phase 4 Terlipressin and albumin
3 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
4 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
5 Randomized Double-Blid Placebo Controlled Trial Assessing Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis In Advanced Cirrhosis Completed NCT00359853 Phase 4 Oral norfloxacin
6 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
7 Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
8 Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study Completed NCT01769040 Phase 4 Rifaximin;placebo
9 The Use of Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
10 Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903): A Multicenter, Single-blind, Randomised Controlled Trial Recruiting NCT04028323 Phase 4 Terlipressin;Octreotide
11 Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment: a Double-blind Randomized Placebo-controlled Trial Recruiting NCT03024684 Phase 4 Atorvastatin;Placebo Oral Tablet
12 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
13 Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
14 Terlipressin as Treatment of Patients With Cirrhosis and Hepatorenal Syndrome. Effect on Survival and Renal Function. Multicenter, Randomized and Prospective Study Suspended NCT00287664 Phase 4 terlipressin
15 Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality Terminated NCT02034279 Phase 4 Albumin
16 Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis Terminated NCT00570960 Phase 4 Dextran 70
17 Terlipressin Given As I.V. Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (Hrs): Preliminary Results Of A Randomized Controlled Clinical Study. Unknown status NCT00742690 Phase 2, Phase 3 terlipressin given by intravenous boluses and albumin;terlipressin given by continuous intravenous infusion and albumin
18 Principal Investigator Unknown status NCT01455337 Phase 3 pentoxifylline;Prednisolone
19 A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase II Trial to Evaluate Late Introduction of Cyclosporine or Everolimus Versus a 5-day Delay of Cyclosporine in Combination With MMF in Liver Transplant Recipients With MELD-Scores≥25 Unknown status NCT01023542 Phase 2, Phase 3 delayed, low-dose CNI;BU-CNI;BU-Everolimus
20 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1 Completed NCT00089570 Phase 3 terlipressin;Placebo
21 The Use of Midodrine, Octreotide and Albumin in Refractory Ascites Completed NCT00240045 Phase 2, Phase 3 Midodrine, albumin, octreotide LAR;midodrine, octreotide, albumin
22 A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 (The CONFIRM Study) Completed NCT02770716 Phase 3 Terlipressin
23 Phase 3, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (REVERSE Trial) Completed NCT01143246 Phase 3 Terlipressin;Placebo
24 Noradrenalin vs Terlipressin in Patients With Hepatorenal Syndrome.A Prospective, Randomized Study Completed NCT00370253 Phase 3 Terlipressin;Noradrenalin
25 NORADRENALINE VERSUS TERLIPRESSIN IN THE TREATMENT OF TYPE 2 HEPATORENAL SYNDROME:A RANDOMIZED STUDY Completed NCT01637454 Phase 3 Noradrenaline;Terlipressin
26 Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. A Randomized, Controlled and Double Blind Study. Completed NCT00502086 Phase 3
27 Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis Completed NCT01809132 Phase 2, Phase 3 Anakinra;Pentoxifylline;Zinc Sulfate;Methylprednisolone
28 Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy Completed NCT02134626 Phase 3 Simvastatin;Placebo pill
29 Randomized Trial, Masked, and Placebo Controlled to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension Completed NCT01456286 Phase 2, Phase 3 sapropterin
30 Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites Completed NCT02173288 Phase 2, Phase 3 Standard medical therapy;Tolvaptan;Midodrine
31 Efficacy of Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin. A Multi-center Randomized Controlled Study Completed NCT00986817 Phase 3 Terlipressin;Placebo
32 Effect of Metoprolol Succinate in Cardiac Remodeling Related to Nonalcoholic Cirrhosis. Randomized Study. Completed NCT01676285 Phase 3 Metoprolol succinate;placebo
33 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
34 A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients With Impaired Renal Function. (PATRON-Study) Completed NCT00604357 Phase 3 anti-CD 25 mAb, Sirolimus, MMF
35 The Effects of Anti-Viral Therapy on the Clinical Status, Quality of Life, and Survival of Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection Completed NCT02597166 Phase 3 Ledipasvir/Sofosbuvir
36 Comparison of The Effectiveness of Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1 Recruiting NCT03822091 Phase 3 Terlipressin;Terlipressin and Noradrenaline
37 Pros & Cons of Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1 in Intensive Care Unit. Recruiting NCT03455322 Phase 2, Phase 3 norepinephrine versus midodrine & octreotide
38 Single Centre, Prospective, Open, Non Controlled, Pilot Study for Efficacy and Security Evaluation of Low Nephrotoxicity Immunosuppression, Based on the Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction Recruiting NCT01453218 Phase 3 ATeGe-Fresenius
39 Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins? Recruiting NCT02443285 Phase 3 Cefotaxime;ceftriaxone
40 Granulocyte Colony Stimulating Factor Therapy In Decompensated Cirrhosis Of Liver: A Double Blinded Single Centre Randomised Controlled Trial Recruiting NCT03911037 Phase 2, Phase 3 G-CSF;Placebo
41 Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis Active, not recruiting NCT02281929 Phase 3 Amoxicillin;Placebo;Prednisolone
42 Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation Not yet recruiting NCT03206658 Phase 3 Spironolactone 25 mg;Placebo oral capsule
43 Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome (HRS): An Open Multicentric Randomized Study Terminated NCT00742339 Phase 2, Phase 3 Terlipressin plus albumin;Midodrine plus octreotide plus human albumin
44 Randomized, Double-Blind, Placebo-Controlled Trial Assessing Norfloxacin in the Prevention of Complications in Patients With Cirrhosis and Severe Liver Failure Terminated NCT01037959 Phase 3 Norfloxacin;Placebo
45 Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Stress Doses of Hydrocortisone on Renal Function and on Liver and Systemic Haemodynamics Unknown status NCT00657306 Phase 2 hydrocortisone;dextrose solution 5%
46 Effect of Intravenous Albumin (Standard vs Dose Reduced Regimen) On Renal Impairment and Mortality in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis: A Double Blind Randomized Clinical Trial Unknown status NCT00852800 Phase 2 Albumin;Albumin
47 An Exploratory Study of FE999908 in Patients With Hepatorenal Syndrome Type 1 Completed NCT01373606 Phase 1, Phase 2 Terlipressin
48 A Multi-Center, Double-Blind, Randomized, Controlled Study to Determine the Safety and Pharmacokinetics of Ifetroban Injection in Hepatorenal Syndrome Completed NCT01436500 Phase 2 Ifetroban Injection;Placebo
49 Prospective Pilot Study Assessing Safety and Efficacy of Single Pass Albumin Dialysis in Patients With Acute on Chronic Liver Failure Completed NCT00764049 Phase 1, Phase 2
50 Effect of Administration of Intravenous Albumin and Oral Midodrine on Renal Function in Patients With Cirrhosis and Functional Renal Impairment Completed NCT01133795 Phase 2 Midodrine plus Albumin

Search NIH Clinical Center for Hepatorenal Syndrome

Cochrane evidence based reviews: hepatorenal syndrome

Genetic Tests for Hepatorenal Syndrome

Anatomical Context for Hepatorenal Syndrome

MalaCards organs/tissues related to Hepatorenal Syndrome:

41
Liver, Kidney, Bone, Neutrophil, Heart, Testes, Brain

Publications for Hepatorenal Syndrome

Articles related to Hepatorenal Syndrome:

(show top 50) (show all 2264)
# Title Authors PMID Year
1
Balancing volume resuscitation and ascites management in cirrhosis. 9 38
20124894 2010
2
Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies. 9 38
20124895 2010
3
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. 9 38
19877168 2010
4
Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. 9 38
19238094 2009
5
Poor outcomes with treatment of hepatorenal syndrome type 1 with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature. 9 38
19918689 2009
6
Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. 9 38
19413694 2009
7
The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. 9 38
18492024 2009
8
Management of hepatorenal syndrome. 9 38
18539334 2008
9
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. 9 38
18471512 2008
10
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. 9 38
17939047 2008
11
Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. 9 38
18197961 2008
12
Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. 9 38
17886336 2008
13
Ascites in cirrhosis: a review of management and complications. 9 38
17890787 2007
14
[Hepatorenal syndrome: pathogenesis and treatment]. 9 38
17760404 2007
15
Possible increased risk of pulmonary edema in patients with hepatorenal syndrome on adding octreotide to albumin / noradrenaline therapies. 9 38
17496406 2007
16
Role of endothelin and endothelin receptor antagonists in renal disease. 9 38
16919017 2006
17
The management of severe alcoholic liver disease and variceal bleeding in the intensive care unit. 9 38
16543796 2006
18
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. 9 38
16393283 2006
19
Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. 9 38
16393223 2005
20
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. 9 38
16123966 2005
21
A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. 9 38
16108036 2005
22
Preoperative optimization of patients with liver disease. 9 38
16534358 2005
23
The use of albumin in patients with decompensated cirrhosis: the case in favor. 9 38
15729966 2005
24
Hepatorenal syndrome: a dreaded complication of end-stage liver disease. 9 38
15667508 2005
25
[Role of albumin in the treatment of hepatorenal syndrome in cirrhosis]. 9 38
15710088 2005
26
[Advances in therapy for ascites and hepatorenal syndrome]. 9 38
15650969 2005
27
Reconsidering hepatorenal syndrome. Throw in the towel? Not so fast! 9 38
15620124 2004
28
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. 9 38
15239086 2004
29
Terlipressin and albumin combination treatment in hepatorenal syndrome. 9 38
15244209 2003
30
Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. 9 38
14563190 2003
31
Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome. 9 38
12867805 2003
32
Terlipressin and albumin for the hepatorenal syndrome. 9 38
12668990 2003
33
Albumin versus crystalloid therapy in the management of hepatorenal syndrome: a model for using meta analysis in cost effectiveness studies and the design of clinical trials. 9 38
14728474 2003
34
Hepatorenal syndrome. 9 38
15094702 2003
35
Review article: albumin for circulatory support in patients with cirrhosis. 9 38
12423450 2002
36
Characterization of treatment dose delivered by albumin dialysis in the treatment of acute renal failure associated with severe hepatic dysfunction. 9 38
12425489 2002
37
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. 9 38
12297842 2002
38
Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. 9 38
12143045 2002
39
[The use of albumin infusion in decompensated liver cirrhosis]. 9 38
11899505 2002
40
Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. 9 38
11778928 2001
41
[Clinical study on hepatitis D virus-positive patients died from severe hepatitis B]. 9 38
11509140 2001
42
Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. 9 38
10905585 2000
43
Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. 9 38
10827226 2000
44
Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. 9 38
10728802 2000
45
Acute renal failure associated with liver disease in India: etiology and outcome. 9 38
11041294 2000
46
Plasma levels of endothelin-1 in patients with the hepatorenal syndrome after successful liver transplantation. 9 38
11052272 2000
47
Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis. 9 38
10638019 1999
48
Serum endothelin and atrial natriuretic peptide in cirrhotic patients with ascites and hepatorenal syndrome. 9 38
9830237 1998
49
Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. 9 38
9425914 1998
50
Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. 9 38
9007721 1996

Variations for Hepatorenal Syndrome

Expression for Hepatorenal Syndrome

Search GEO for disease gene expression data for Hepatorenal Syndrome.

Pathways for Hepatorenal Syndrome

Pathways related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.6 F2 ALB
2 10.02 IL18 F2

GO Terms for Hepatorenal Syndrome

Cellular components related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 REN NPPA IL18 F2 EDN1 CST3
2 endoplasmic reticulum lumen GO:0005788 9.33 F2 CST3 ALB
3 extracellular space GO:0005615 9.17 REN NPPA IL18 F2 EDN1 CST3

Biological processes related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of smooth muscle cell proliferation GO:0048661 9.48 IL18 EDN1
2 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.46 IL18 EDN1
3 cellular protein metabolic process GO:0044267 9.46 NPPA F2 CST3 ALB
4 negative regulation of proteolysis GO:0045861 9.43 F2 CST3
5 regulation of blood pressure GO:0008217 9.43 REN NPPA EDN1
6 regulation of blood vessel size GO:0050880 9.4 NPPA EDN1
7 response to muscle stretch GO:0035994 9.37 NPPA EDN1
8 positive regulation of renal sodium excretion GO:0035815 9.32 EDN1 AVPR1A
9 cellular response to water deprivation GO:0042631 8.96 AVPR1A AQP2
10 positive regulation of heart rate GO:0010460 8.8 NPPA EDN1 AVPR1A

Molecular functions related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.61 REN NPPA IL18 F2 EDN1 CST3
2 signaling receptor binding GO:0005102 8.92 REN NPPA F2 EDN1

Sources for Hepatorenal Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....